The bone scan as a tumour marker in prostatic carcinoma.
The technetium methylene diphosphate bone scan was elevated in 100 consecutive new patients presenting with carcinoma of the prostate. 48% of the patients has a positive bone scan at the  initial diagnosis. The scan was more helpful than the skeletal X-ray in the diagnosis of bone metastases: 23% of the X-ray-negative patients were scan-positive. Serial bone scans were more sensitive than either X-rays or serum acid phosphatase in following the progress of the disease. It is concluded that the bone scan in patients with prostatic carcinoma can be used as a reliable tumour marker, especially for monitoring the course of metastases.
D001842:Bone and Bones / Q000000981:diagnostic imaging*; D011756:Diphosphates; D004164:Diphosphonates; D012968:Etidronic Acid; D006801:Humans; D008297:Male; D015609:Organotechnetium Compounds; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D011859:Radiography; D011877:Radionuclide Imaging; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D016698:Technetium Tc 99m Pyrophosphate
D011756:Diphosphates; D004164:Diphosphonates; D015609:Organotechnetium Compounds; C019561:technetium Tc 99m etidronate; D016698:Technetium Tc 99m Pyrophosphate; D013667:Technetium; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate